Showing 1 - 2 results of 2 for search 'Cuizhen Niu', query time: 0.02s Refine Results
  1. 1
    346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

    346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) by Christian Poehlein, Joseph Burgents, Christian Gratzke, Cuizhen Niu

    Published 2020-11-01
    Article
  2. 2
    Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study

    Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study by Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. Diede, Haiyan Dai, Cuizhen Niu, Jianfeng Li, Jun Guo

    Published 2022-10-01
    Get full text
    Article

Search Tools: